Cystic Fibrosis Foundation issued the following clinical trial alert in the month of October.
October 16, 2019
Status: Enrolling
Description: This study will look at the safety and effectiveness of three CFTR modulators when taken in combination: VX-445 (elexacaftor), tezacaftor, and ivacaftor. CFTR modulators are drugs intended to help CFTR protein function closer to normal.
Age: 12 Years and Older
Mutation: One Copy F508del
Fev1% Predicted: 40 to 90%
Number of Visits: 8
Length of Participation: 20 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT04058353